Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies Published September 2019 Citation Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR. . ESMO Annual Congress. . https://www.annalsofoncology.org/article/S0923-7534(19)59501-1/pdf Authors:Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR Sources:ESMO Annual Congress Share Posted inPublicationsComparative effectivenessMelanoma More publicationsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancerISPOR 2025April 2025Using regression discontinuity in time design for real-world comparative effectiveness: A case study for the second-line use of pembrolizumab in advanced non-small cell lung cancerChen N, Zemplenyi A, Adamson B, et al. Publication summaryPublicationsComparative effectivenessNon-small cell lung cancerESMO OpenJanuary 2025Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world settingRugo H.S., Layman R.M., Lynce F, et al. Real-world evidencePublication summaryPublicationsComparative effectivenessMetastatic breast cancer